Diginex's stock plummets 93% despite Doctolib deal and record growth
Diginex has secured a major client in French healthcare provider Doctolib for its carbon accounting software. Despite this deal and record revenue growth, the company's stock price continues to fall sharply. On Friday, Diginex's share price dropped to €0.406, hitting another 52-week low. This decline comes even after the company announced its partnership with Doctolib in early 2026. Over the past year, the stock has lost around 93% of its value, falling from a peak of $39.90 in October 2025.
The broader market also faced turbulence last week. The Nasdaq 100 fell 2.36% to 23,070 points, while Brent crude rose over 5.5% to around $114 per barrel. Investors are increasingly avoiding risky small-cap stocks, adding pressure on companies like Diginex. U.S. consumer confidence has also slumped to a one-year low of 53.3 points, according to the University of Michigan.
Diginex now risks delisting if its stock falls further below Nasdaq's minimum $1.00 requirement. Without clear signs of sustainable profitability, the gap between operational progress and market performance may remain. Diginex's stock struggles persist despite positive business updates. The company's future on Nasdaq depends on reversing its share price decline. Meanwhile, broader economic uncertainty continues to weigh on investor sentiment.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
- Inspired & Paddy Power Extend Virtual Sports Partnership for UK & Ireland Retail
- South West & South East England: Check & Object to Lorry Operator Licensing Now
